Incidência de neutropenia induzida por quimioterapia no tratamento do câncer colorretal

Palavras-chave: Neutropenia, Neoplasias Colorretais, Incidência, Epidemiologia, Protocolos de Quimioterapia Combinada Antineoplásica.

Resumo

Objetivo: analisar a incidência de neutropenia em pacientes com câncer colorretal, submetidos ao tratamento quimioterápico. Métodos: revisão integrativa, realizada nas bases de dados National Library of Medicine National Institutes of Health, Cumulative Index to Nursing and Allied Health Literature, Literatura Latino-Americana e do Caribe em Ciências da Saúde e SciVerse Scopus. Resultados: identificaram-se 499 artigos, dos quais 15 atenderam aos critérios de inclusão, publicados entre 2006 e 2016 e analisados na íntegra. A neutropenia foi a toxicidade hematológica mais relatada em 12 (80,0%) estudos, e a segunda mais comum em três (20,0%), em graus variáveis, sendo responsável pela redução e/ou atraso de doses em seis (40,0%) estudos. Conclusão: os estudos incluídos nesta revisão evidenciaram que a neutropenia em pacientes com câncer colorretal em tratamento quimioterápico tem incidência baixa em diferentes graus, apesar das associações significativamente alta das taxas de neutropenia, como o evento adverso mais comum nos diferentes regimes analisados.

Referências

Freire MEM, Costa SFG, Lima RAG, Sawada NO. Health-related quality of life of patients with cancer in palliative care. Text Contexto Enferm. 2018; 27(2):1-13. doi: http://dx.doi.org/10.1590/0104-070720180005420016

Nicolussi AC, Sawada NO, Cardozo FMC, Andrade V, Paula JM. Health-related quality of life of câncer patients undergoing chemotherapy. Rev Rene. 2014; 15(1):132-40. doi: http://dx.doi.org/10.15253/2175-6783.2014000100017

Toneti BF, Paula JM, Nicolussi AC, Sawada NO. Health-related quality of life of the elderly with cancer in adjuvant treatment. Rev Rene. 2014; 15(6):1030-8. doi: http://dx.doi.org/10.15253/2175-6783.2014000600017

Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, et al. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015; 15:786. doi: http://doi.org/10.1186/s12885-015-1712-0

Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer. 2012; 12:271. doi: http://doi.org/10.1186/1471-2407-12-271

Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, et al. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci. 2012; 103(8):1502-7. doi: https://doi.org/10.1111/j.1349-7006.2012.02320.x

Martins AVC, Didier MEV. Neutropenia febril. In: Fonseca RP, Coelho OFL. Urgências oncológicas no pronto-socorro: uma abordagem para o clínico. São Paulo: Atheneu; 2015. p.187-96.

Yoshida Y, Hoshino S, Aisu N, Mogi A, Yamada T, Kojima D, et al. Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? Support Care Cancer. 2015; 23(6):1623-7. doi: https://doi.org/10.1007/s00520-014-2518-3

Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm. 2008; 17(4):756-64. doi: http://dx.doi.org/10.1590/S0104-07072008000400018

Fineout-Overholt E, Stillwell SB. Asking compelling, clinical questions. In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare: a guide to best practice [Internet]. 2011 [cited Jan. 19, 2019]. Available from: http://file.zums.ac.ir/ebook/208-Evidence-Based%20Practice%20in%20Nursing%20&%20Healthcare%20-%20A%20Guide%20to%20Best%20Practice,%20Second%20Edition-Be.pdf

Ursi ES, Galvão CM. Prevenção de lesões de pele no perioperatório: revisão integrativa da literatura. Rev Latino-Am Enfermagem. 2006; 14(1):124-31. doi: http://dx.doi.org/10.1590/S0104-11692006000100017

Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009; 6(6):e1000097. doi: https://doi.org/10.1371/journal.pmed.1000097

Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, et al. A phase ii clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol. 2013; 43(11):1080-6. doi: https://doi.org/10.1093/jjco/hyt127

Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013; 13:611. doi: https://doi.org/10.1186/1471-2407-13-611

Uygyn K, Bilici A. Kaya S, Ustaalioglu BBO, Yildiz R, Temiz S, et al. Xeliri plus bevacizumab compared with folfiri plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev. 2013; 14(4):2283-8. doi: http://dx.doi.org/10.7314/APJCP.2013.14.4.2283

Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77(2):113-9. doi: https://doi.org/10.1159/000229787

Shigeta K, Hasegawa H, Okabayashi K, Tsuruta M, Ishii Y, Endo T, et al. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Int J Cancer. 2016; 139(4):946-54. doi: https://doi.org/10.1002/ijc.30127

Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience. Clin Colorectal Cancer. 2014; 13(3):199-206. doi: https://doi.org/10.1016/j.clcc.2014.06.002

Roque VMN, Forones NM. Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas. Arq Gastroenterol. 2006; 43(2):94-101. doi: http://dx.doi.org/10.1590/S0004-28032006000200007

Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Ito Y, et al. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. Asia Pac J Clin Oncol. 2015; 13(2):132-7. doi: https://doi.org/10.1111/ajco.12405

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Eng J Med. 2014; 371(17):1609-18. doi: https://doi.org/10.1056/NEJMoa1403108

Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M et al. Oxaliplatin/fl uorouracil/leucovorin (FOLFOX4 and modifi ed FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007; 12(3):218-23. doi: http://doi.org/10.1007/s10147-007-0658-x

Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori. 2006; 92(4):290-4. doi: https://doi.org/10.1177/030089160609200405

Huang J, Yen C, You Y, Wang C, Lan Y, Lai C, et al. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study. Chang Gung Med J [Internet]. 2006 [cited 2018 Apr 29]; 29:297-305. Available from: http://cgmj.cgu.edu.tw/2903/290311.pdf

Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicenter randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94(6):798-805. doi: https://doi.org/10.1038/sj.bjc.6603011

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of dpyd 2a to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016; 34(3):227-34. doi: https://doi.org/10.1200/JCO.2015.63.1325

Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO. Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy. Rev Latino-Am Enfermagem. 2014; 22(2):301-8. doi: http://dx.doi.org/10.1590/0104-1169.3305.2416

Tan X, Wen Q, Wang R, Chen Z. Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies. Expert Rev Anticancer Ther. 2017; 17(11):1077-85. doi: http://dx.doi.org/10.1080/14737140.2017.1380521

Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capeci- tabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer. 2009; 100(11):1720-4. doi: https://doi.org/10.1038/sj.bjc.6605075

Koutras AK, Kalofonos HP. Myelotoxicity in cancer patients treated with chemotherapy: negative or positive prognostic factor? Clin Cancer Res. 2008; 14(22):7579. doi: https://doi.org/10.1158/1078-0432.CCR-08-1519

Publicado
2019-04-03
Seção
Artigos de Revisão